TD Cowen lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $108 from $110 and keeps a Buy rating on the shares. The firm updated its model while trimming restimates ahead of Q1 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Advancing Neurology Franchise Underscored by Zilganersen’s Strong Phase III Data in Alexander Disease
- Ionis Expands Its Rare Epilepsy Pipeline With New ASCEND Trial in Dravet Syndrome
- Ionis Pharmaceuticals price target raised to $130 from $95 at Morgan Stanley
- Ionis announces additional results from zilganersen study in AxD
- Ionis Highlights Positive Zilganersen Data in Alexander Disease